Breast Cancer Trial, Recruiting NCT04476485 Sponsor: Shengjing Hospital Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT04476485
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been confirmed by testing to have early-stage invasive breast cancer that is sensitive to the hormones estrogen and/or progesterone
  • People who have already completed 5 years of standard hormone-blocking (endocrine) therapy with no signs of the cancer coming back or spreading
  • People between 18 and 70 years of age
  • People who have at least one of the following features of their cancer: a high cell growth rate (KI67 of 30% or more); a tumor larger than 2 cm; cancer that has spread to nearby lymph nodes; cancer cells that look very abnormal under a microscope (grade III); cancer cells found inside nearby blood or lymph vessels; or a cancer type known as HER-2 positive

Who may not be able to join:

  • People who have a history of any other type of cancer
  • People who have serious problems with major organs such as the heart, liver, or kidneys, or whose general health is too poor to handle extended treatment
  • People who have severe bone thinning (osteoporosis) or serious problems with blood fat levels, or whose health does not allow them to tolerate hormone-blocking therapy
  • People who are already taking part in another clinical trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jin-Qi Xue, Shengjing Hospital

Phone: 18940254967

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shengjing Hospital
Registry
ClinicalTrials.gov
Start date
19 July 2021
Est. completion
31 December 2021

Where this trial is recruiting

🇨🇳 China

Primary endpoints

disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov